New treatment modalities in Alzheimer's disease

Table 1 Potential treatments related to BACE1 and p-tau undergoing clinical trials

Target	Drug	Study phase	Expected completion date	Results
BACE1	Lanabecestat	2	September 2019
	JNJ-54861911	2	October 2022
	Elenbecestat	3	December 2020
	Verubecestat	3	March 2021
	LY450139	3	Completed April 2011	Not effective
P-tau	IONIS-MAPTRx	1, 2	February 2020
	JNJ-63733657	1	February 2019
	RO7105705	2	September 2022
	ABBV-8E12	2	June 2021
	AADvac 1	2	June 2019
	BIIB-092	2	September 2020
	BIIB-080	1	February 2020
	TPI-287	1	Completed May 2017
	TRx0237	3	February 2019
	LY3303560	1	June 2019
	MTAU9937A	2	(-) Continuing
	E2814	1	(-) Continuing

BACE1: β-site amyloid precursor protein cleaving enzyme 1; p-tau: Hyperphosphorylated tau peptide.

Table 2 Current clinical trials on stem cells

Clinical Trials. gov identifier	Type of stem cell transplantation	Study phase	Estimated number of participants	Status
NCT02054208	Intraventricular administration of hUCB-MSCs	1/2a	45	Recruiting
NCT02672306	UCMSCs	1/2a	16	Active, not recruiting
NCT02833792	Allogeneic hMSCs	2a	40	Recruiting
NCT02600130	Allogeneic hMSCs	1	30	Recruiting
NCT03117738	Autologous adipose tissue derived MSCs	1/2	60	Recruiting

UCB-MSCs: Umbilical cord blood-derived mesenchymal stem cells; UCMSCs: Umbilical cord mesenchymal stem cells.